阿立哌唑与奥氮平对精神分裂症患者糖脂代谢的影响

Influences of aripiprazole and olanzapine on glycolipid metabolism of schizophrenia patients

目的探讨阿立哌唑与奥氮平对精神分裂症患者糖脂代谢的影响。方法将62例精神分裂症患者随机分为两组，每组31例，研究组口服阿立哌唑治疗，对照组口服奥氮平治疗，观察2个月。于治疗前及治疗2个月末分别检测两组空腹血糖、餐后2小时血糖、胆固醇、甘油三脂、体重指数，对两组检测结果进行对比分析。结果研究组治疗前后各项指标检测结果均无显著变化（P〉0．05）；对照组治疗2个月末空腹血糖、餐后2小时血糖、体重指数均较治疗前有显著提高（P〈0．05或0．01），且均显著高于研究组（P〈0．05或0．01）。结论奥氮平对精神分裂症患者的血糖、血脂、体重有显著影响，而阿立哌唑则无明显影响，值得临床推广应用。

~Abstractl Objective To explore the influence of aripiprazole and olanzapine on glycolipid metabolism of schizophrenia patients. Methods Sixty-two schizophrenics were randomly assigned to two groups, research group took orally aripiprazole and control group did olanzapine for 2 months. Before and after 2 month treatment ,such indexes as blood-fasting sugar（BFS）, post-meal 2-hr blood glucose（P2BG） , cholesterol, triglyceride and body mass index（BMI） were detected and eontrastively analyzed. Results There were no significant changes in detected indexes between pre-and post-treatment in the research group（P〉0.05）; after 2-month treatment,BFS,P2HBG and BMI increased more significantly compared with pretreatment in the control group （P〈0. 05 or 0. 01） and all were higher than in the research group（P〈0. 05 or 0. 01）. Conclusion Olanzapine has notable effects on patients＇ blood glucose ,blood lipid and body weight, and deserves clinical generalization.